Clearance of continuously infused @entity1487 in adults having lung or @entity1820 with or without hepatic XXXX .

@entity1 @entity137 @entity2 @entity348 @entity1820 @entity3 @entity420 @entity1487
The steady-state apparent @entity348 ( @entity348 ) of continuously infused @entity1487 ( @entity1487 ) were determined in 16 adult male @entity1 who were receiving combined @entity1487 -radiation therapy. Seven @entity1 (group A) had Stage III @entity420 or @entity2 ; none had known @entity3 . Five @entity1 had @entity1820 (group B), without known hepatic @entity3 . Four had @entity1820 with evidence of hepatic @entity3 (group C). TBCs were calculated from infusion rates and serum @entity1487 concentration data. The means (standard errors) of the TBCs were: group A, 4.49 (0.53); group B, 6.51 (0.53); group C, 2.96 (0.91) L/kg/h. The difference among the means was found to be significant (p less than 0.002) by one-way ANOVA. Differences among the groups were then examined using 95 percent confidence intervals: group A was not different from group B or group C; however, groups B and C differed from each other. @entity1 with hepatic @entity3 have @entity1487 TBCs about half that of those found in @entity1 without hepatic involvement. Clinically, @entity1 in group C attained the higher serum @entity1487 concentrations known to be radiosensitizing more frequently than @entity1 in the other two groups; differences in @entity137 were not evident. This suggests that administration of an agent that can compete with @entity1487 for hepatic metabolism to @entity1 with rapid clearance might improve the therapeutic efficacy of @entity1487 .
